Substituted cycloalkanes for managing nephrogenic diabetes insipidus
AssigneeNephroDI Therapeutics, Inc.
InventorsJeff SANDS, Janet KLEIN, Ish KHANNA, Sivaram PILLARISETTI
Life of this patent
Estimating the term…
Abstract
In certain embodiments, this disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a compound of Formula I or derivatives thereof, as described herein, to a subject in need thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.
Claims73
1-19. (canceled)
A method for treating nephrogenic diabetes insipidus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound represented by the structure:
- 1,1′-(dodecane-1,12-diyl)bis(cyclopropane-1-carboxamide)
- or a pharmaceutically acceptable salt thereof.
A method for treating nephrogenic diabetes insipidus in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound represented by the structure:
- 1,1′-(decane-1,10-diyl)bis(cyclopropane-1-carboxylic acid)
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.